Philogen S.p.A. is a clinical-stage biotechnology company focused on developing targeted therapies for oncology and chronic inflammatory conditions. The company's core therapeutic strategy relies on "tumor targeting," which utilizes engineered monoclonal antibodies and small organic ligands to deliver bioactive agents, such as cytokines, directly to diseased tissues while sparing healthy cells. Philogen operates through a fully integrated model, managing its own discovery, GMP manufacturing, and clinical trial execution. Its research activities are driven by proprietary platforms, including Antibody Phage Display Libraries and DNA-Encoded Chemical Libraries, primarily conducted at its Swiss subsidiary, Philochem. The company generates revenue through research, licensing, and collaboration agreements with major pharmaceutical partners, alongside research and development services.
